Skip to main content

Lactobacillus acidophilus 74-2 and Bifidobacterium animalis subsp lactis DGCC 420 modulate unspecific cellular immune response in healthy adults

  • 2007-04-18
  • European Journal of Clinical Nutrition 62(5)
    • A. Klein
    • U. Friedrich
    • Heinz Vogelsang
    • Gerhard Jahreis

Abstract

Objective: It was determined whether a combination of Lactobacillus acidophilus (L. acidophilus) 74-2 and Bifidobacterium animalis subsp lactis DGCC 420 (B. lactis 420) affect the faecal microbiota as well as immunological parameters and blood lipids in healthy adults.

Design: A placebo-controlled, double-blinded, randomized crossover trial was conducted.

Subjects: Twenty-six healthy volunteers (mean age 25 years) were recruited by advertising in academical buildings. All of them completed the study.

Methods: After 3-week run-in period, half of the volunteers consumed 300 g/day of yoghurt supplement containing probiotic strains L. acidophilus 74-2 and B. lactis 420, and the other half received the placebo product for a period of 5 weeks. The two groups were crossed during the following 5-week period. Blood and faecal samples were collected at the end of each period. The faecal content of probiotic bacteria, faecal short-chain fatty acids (SCFA), serum lipids and plasma immune system biomarkers were evaluated.

Results: Faecal proportions of L. acidophilus and of B. lactis increased significantly from 0.02 to 0.19 and 0.4 to 1.4% (P<0.05), respectively. Percentages of granulocytes and monocytes showing phagocytic activity were significantly elevated from 92 to 95% during probiotic intervention, whereas their oxidative burst activity and specific immune parameters remained unaffected. Fecal SCFA and serum cholesterol levels were not influenced by the probiotics. However, serum concentrations of triacylglyceroles decreased significantly by 11.6% (P<0.05) in the probiotic supplementation period.

Conclusions: L. acidophilus and B. lactis were recovered in faeces in significantly elevated numbers after supplementation. They are able to modulate unspecific cellular immune response indicated by the increased phagocytic activity.

Research Insights

SupplementHealth OutcomeEffect TypeEffect Size
Bifidobacterium animalis subsp. lactis B420Increased Fecal Probiotic BacteriaBeneficial
Moderate
Bifidobacterium animalis subsp. lactis B420Increased PMN Cell Phagocytic CapacityBeneficial
Moderate
Bifidobacterium animalis subsp. lactis B420Reduced Serum TriacylglycerolsBeneficial
Moderate
Bifidobacterium lactisIncreased Fecal Proportion of Lactobacillus acidophilusNeutral
Moderate
Bifidobacterium lactisIncreased Proportion of Fecal Bifidobacterium lactisNeutral
Moderate
Bifidobacterium lactisReduced Serum TriacylglycerolsBeneficial
Moderate
Bifidobacterium lactis HA-194Increased PMN Cell Phagocytic CapacityBeneficial
Moderate
Bifidobacterium lactis HA-194Reduced Serum TriacylglycerolsBeneficial
Moderate
Bifidobacterium lactis MAK16B42LIncreased PMN Cell Phagocytic CapacityBeneficial
Moderate
Bifidobacterium lactis MAK16B42LReduced Serum TriacylglycerolsBeneficial
Moderate
Lactobacillus acidophilusIncreased PMN Cell Phagocytic CapacityBeneficial
Moderate
Lactobacillus acidophilusReduced Serum Triglyceride LevelsBeneficial
Moderate
Lactobacillus acidophilus HA-122Increased PMN Cell Phagocytic CapacityBeneficial
Moderate
Lactobacillus acidophilus HA-122Reduced Serum TriglyceridesBeneficial
Moderate
Lactobacillus acidophilus L-92Increased Fecal Probiotic BacteriaBeneficial
Moderate
Lactobacillus acidophilus L-92Increased PMN Cell Phagocytic CapacityBeneficial
Moderate
Lactobacillus acidophilus L-92Reduced Serum TriacylglycerolsBeneficial
Moderate
Lactobacillus acidophilus NCIMB 30333Increased PMN Cell Phagocytic CapacityBeneficial
Moderate
Lactobacillus acidophilus NCIMB 30333Reduced Serum TriacylglycerolsBeneficial
Moderate
Lactobacillus acidophilus R0418Increased Fecal Probiotic BacteriaBeneficial
Moderate
Lactobacillus acidophilus R0418Increased PMN Cell Phagocytic CapacityBeneficial
Moderate
Lactobacillus acidophilus R0418Reduced Serum Triglyceride LevelsBeneficial
Moderate
Lactobacillus acidophilus SD-5212Improved Phagocytic ActivityBeneficial
Small
Lactobacillus acidophilus SD-5212Increased Fecal Probiotic BacteriaBeneficial
Moderate
Lactobacillus acidophilus SD-5212Reduced Serum TriglyceridesBeneficial
Moderate
Lactobacillus acidophilus UALa01Increased PMN Cell Phagocytic CapacityBeneficial
Moderate
Lactobacillus acidophilus UALa01Reduced Serum TriacylglycerolsBeneficial
Moderate
Lactobacillus lactis LI-23Increased PMN Cell Phagocytic CapacityBeneficial
Moderate
Lactobacillus lactis LI-23Reduced Serum TriacylglycerolsBeneficial
Moderate

Pillser helps you make informed health decisions by providing comprehensive, unbiased information about supplements. This includes detailed research on supplement ingredients, their benefits, potential risks, and their overall efficacy. You can contribute by sharing your feedback and suggestions.

Send us an email at support@pillser.com.